Progress in cystic fibrosis and the CF Therapeutics Development Network

Academic Article

Abstract

  • Cystic fibrosis (CF), the most common life-shortening genetic disorder in Caucasians, affects approximately 70 000 individuals worldwide. In 1998, the Cystic Fibrosis Foundation (CFF) launched the CF Therapeutics Development Network (CF-TDN) as a central element of its Therapeutics Development Programme. Designed to accelerate the clinical evaluation of new therapies needed to ful fil the CFF mission to control and cure CF, the CF-TDN has conducted 75 clinical trials since its inception, and has contributed to studies as varied as initial safety and proof of concept trials to pivotal programmes required for regulatory approval. This review highlights recent and significant research efforts of the CF-TDN, including a summary of contributions to studies involving CF transmembrane conductance regulator (CFTR) modulators, airway surface liquid hydrators and mucus modifiers, anti-infectives, anti-inflammatories, and nutritional therapies. Efforts to advance CF biomarkers, necessary to accelerate the therapeutic goals of the network, are also summarised.
  • Authors

    Digital Object Identifier (doi)

    Author List

  • Rowe SM; Borowitz DS; Burns JL; Clancy JP; Donaldson SH; Retsch-Bogart G; Sagel SD; Ramsey BW
  • Start Page

  • 882
  • End Page

  • 890
  • Volume

  • 67
  • Issue

  • 10